The FDA has accepted for review the NDA for Chiesi’s single inhaler triple therapy for the maintenance treatment of asthma in adults.
Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback